Albert Font

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

Johann S. de Bono, Ugo De Giorgi, Daniel Nava Rodrigues et al. · Clinical Cancer Research · 2018 · 303 citations

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m²) and the Currently Approved Dose (25 mg/m²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA

Mario A. Eisenberger, Anne-Claire Hardy-Bessard, Choung‐Soo Kim et al. · Journal of Clinical Oncology · 2017 · 282 citations

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Vincenza Conteduca, Daniel Wetterskog, Mansour T. A. Sharabiani et al. · Annals of Oncology · 2017 · 263 citations · Full text

Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

Jervoise Andreyev, A. R. Norman, David Cunningham et al. · British Journal of Cancer · 2001 · 204 citations · Full text

Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer

Eva Martínez-López, Albert Abad, Albert Font et al. · Gastroenterology · 1998 · 149 citations · Full text

Prognostic Marker, Allelic Loss, Oncology +10